Poster Session 4 – Thursday, December 9, 2021: 5:00 pm – 6:30 pm CT
   
  Tumor Cell and Molecular Biology: Drug Resistance
P4-01-01 Resistance to next generation tyrosine kinase inhibitors (TKIs) in HER2-positive breast cancer (BC): Role of HER and PIK3CA mutations and development of new treatment strategies and study models
Bose S, Mistry R, Liu CC, Nanda S, Qin L, Selenica P, Gazzo A, Zhu Y, Mancini MA, Stossi F, Diala I, Eli LD, Weigelt B, Reis-Filho JS, Rimawi MF, Osborne CK, Schiff R, Veeraraghavan J. Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX; Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX; Lester and Sue Smith Breast Center and Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY; Department of Molecular and Cellular Biology and Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, Houston, TX; Puma Biotechnology Inc., Los Angeles, CA; Lester and Sue Smith Breast Center, Dan L. Duncan Comprehensive Cancer Center and Department of Medicine, Baylor College of Medicine, Houston, TX; Lester and Sue Smith Breast Center, Department of Molecular and Cellular Biology, Dan L. Duncan Comprehensive Cancer Center and Department of Medicine, Baylor College of Medicine, Houston, TX; Lester and Sue Smith Breast Center, Department of Molecular and Cellular Biology, Dan L. Duncan Comprehensive Cancer Center and Department of Medicine, Baylor College of Medicine, Houston, TX.
P4-01-02 A spectrum of secondary mutations in HER2 augment breast cancer cell growth and reduce neratinib sensitivity in HER2-mutant breast cancer
Marin AA, Al Mamun A, Akamatsu H, Ye D, Sudhan D, Brown B, Brewer MR, Eli L, Meiler J, Arteaga CL, Hanker AB. UT Southwestern Simmons Comprehensive Cancer Center, Dallas, TX; Vanderbildt University, Nashville, TN; Wakayama Medical University, Wakayama, Japan4Vanderbilt University, Nashville, TN; Vanderbildt University, Nashville, TN; Puma Biotechnology, Los Angeles, CA; UT Southwestern Medical Center, Dallas, TX.
P4-01-03 Multiomics data reveal novel biomarkers for CDK4/6 resistance
Kalari KR, Thompson KJ, Sinnwell J, Tang X, Suman VJ, He J, Byeon SK, Pandey A, Eyman Casey A, Vedell PT, Moyer AM, Moreno-Aspitia A, Northfelt DW, Liu MC, Haddad TC, Chumsri S, Peethambaram P, Ruddy KJ, Giridhar KV, Leon-Ferre RA, Weinshilboum RM, Wang L, O’ Sullivan CC, Goetz MP. Mayo Clinic, Rochester, MN; Mayo Clinic, Jacksonville, FL; Mayo Clinic, Phoenix, AZ.
P4-01-04 FGFR inhibitor mediated dismissal of SWI/SNF complexes from YAP-dependent enhancers induces therapeutic resistance in triple negative breast cancer
Li Y, Qiu X, Wang X, Liu H, Geck R, Tewari A, Chow K-H, Xiao T, Cejas P, Nguyen Q-D, Long H, Liu SX, Toker A, Brown M. Dana-Farber Cancer Institute, Boston, MA; Beth Israel Deaconess Medical Center, Boston, MA.
P4-01-05 Multi-omics data shows downregulation of mismatch repair, purin and tublin pathways in AR-negative triple-negative chemotherapy-resistant tumors
Kalari KR, Suman VJ, Tang X, Sinnwell JP, Thompson KJ, Vedell PT, Carter JM, McLaughlin SA, Moreno Aspitia A, Northfelt DW, Gray RJ, Weinshilboum R, Wang L, Boughey JC, Goetz M. Mayo Clinic, Rochester, MN.
P4-01-06 Genomic and transcriptomic analysis reveals known and novel resistance mechanisms to CDK4/6 inhibitors and sensitivity factors for the response to triplet therapy (palbociclib + everolimus + exemestane) in a phase I/IIb study in hormone-receptor positive (HR+)/HER2- metastatic breast cancer (MBC) after progression on a CDK4/6 inhibitor (CDK4/6i)
Gomez Tejeda Zanudo J, Barroso-Sousa R, Jain E, Buendia-Buendia J, Li T, Tayob N, Rees R, Pereslete A, Ferreira AR, Abravanel DL, Helvie K, Partridge AH, Overmoyer B, Winer EP, Wagle N, Tolaney SM. Broad Institute of MIT and Harvard, Cambridge, MA; Hospital Sirio-Libanes, Brasília, Brazil; Dana-Farber Cancer Institute, Boston, MA; Champalimaud Clinical Center, Lisbon, Portugal.
P4-01-07 Withdrawn
P4-01-08 Morphological and functional plasticity of mitochondria in chemoresistant triple negative breast cancer
Baek LM, Lee J, Barrish JP, Lim B, Chang JT, Lorenzi PL, Porter W, Echeverria GV. Baylor College of Medicine, Houston, TX; Texas Children's Hospital, Houston, TX; University of Texas Health Science Center, Houston, TX; M.D. Anderson Cancer Center, Houston, TX; Texas A&M University, College Station, TX.
P4-01-09 The WAVE3 phosphorylation / β-catenin oncogenic signaling axis promotes chemoresistance and cancer stemness in triple negative breast cancer
Wang W, Rana P, Alkrekshi A, Markovic V, Sossey-Alaoui K. Case Western Reserve University, Cleveland, OH.
P4-01-10 A kinase inhibitor library screen reveals novel candidates that reverse CDK4/6 inhibitor resistance in CDK6 amplified HR(+) breast cancer
Lai J-I, Zhuang Y-Z, Lin T-Y, Chao T-C, Liu C-Y, Tseng L-M. Taipei Veterans General Hospital, Taipei, Taiwan; Institute of Clinical Medicine, School of Medicine, National Yang-Ming Chiao Tung University, Taipei, Taiwan.
P4-01-11 UBQLN4 regulates cisplatin-resistance in triple-negative breast cancer by targeting BAT3 for proteasomal degradation
Shoji Y, Yokoe T, Bostick PJ, Shiloh Y, Hoon DSB, Bustos MA. Department of Translational Molecular Medicine, Division of Molecular Oncology, Saint John’s Cancer Institute (SJCI) at Providence Saint John’s Health Center (SJHC), Santa Monica, CA; Mayo Clinic Care Network, Baton Rouge General Medical Center, Louisiana, LA; The David and Inez Myers Laboratory for Cancer Research Department of Human Molecular Genetics and Biochemistry Tel Aviv University School of Medicine, Tel Aviv, Israel.
P4-01-12 Withdrawn
P4-01-13 Low tumor TLR9 expression results in resistance to growth inhibitory and autophagy responses to common breast cancer treatments
Selander K, Klaper J, Petruk N, Ramm M, Jukkola A, Eskelinen E-L. University Hospital of Oulu, Oulu, Finland; Nataliia Petruk, Turku, Finland; University of Turku, Turku, Finland; University Hospital of Tampere, Tampere, Finland.
P4-01-14 The RXR agonist, IRX4204, increases the anti-tumor activity of HER2-targeted therapies in HER2-amplified breast cancer
Moyer CL, Mazumdar A, Hill J, Sanders ME, Brown P. MD Anderson Cancer Center, Houston, TX; Io Therapeutics, Inc., Santa Ana, CA.
P4-01-15 Eribulin treatment for hormone receptor positive breast cancer cells with resistant to endocrine therapy promotes re-expression of estrogen receptor
Goto Q, Kashiwagi S, Fujioka M, Ishihara S, Asano Y, Morisaki T, Noda S, Takashima T, Ohira M, Hirakawa K. Osaka City University Graduate School of Medicine, Osaka, Japan.
P4-01-16 Overcome chemoresistance of triple-negative breast cancer by inhibiting the RNA-binding protein HuR
Wei L, Zhang Q, Zhong C, Aubé J, Welch DR, Wu X, Xu L. Bioengineering Program, the University of Kansas, Lawrence, KS; Department of Molecular Biosciences, the University of Kansas, Lawrence, KS; Department of Electrical Engineering and Computer Science, The University of Kansas, Lawrence, KS; Division of Chemical Biology and Medicinal Chemistry, UNC Eshelman School of Pharmacy, The University of North Carolina, Chapel Hill, NC; Department of Cancer Biology, The University of Kansas Medical Center; The University of Kansas Cancer Center, The University of Kansas Medical Center, Kansas City, KS; Department of Molecular Biosciences, The University of Kansas; The University of Kansas Cancer Center, The University of Kansas Medical Center, Lawrence, KS; Department of Molecular Biosciences, the University of Kansas; The University of Kansas Cancer Center, The University of Kansas Medical Center; Department of Radiation Oncology, The University of Kansas Medical Center, Lawrence, KS.
P4-01-17 Preventing adaptive therapeutic resistance to CDK4/6 inhibition with CDK8/19 inhibitors
Mack A, Yastrebova M, Khamidullina A, Sharko A, Ding X, Bowe S, Sashi N, Safa S, Digsby K, Eckstrom A, Sikirzhitski V, Lim C-u, Tatarskiy V, Roninson I, Broude E. University of South Carolina, Columbia, SC; Institute of Gene Biology Russian Academy of Sciences, Moscow, Russian Federation.
P4-01-18 Acquired sensitivity strategies in ER+ breast cancer progressing on CDK4/6 and mTOR inhibitors
Farmaki E, Emond R, Cosgrove P, Bild A. City of Hope, Monrovia, CA.
   
  Tumor Cell and Molecular Biology: Endocrine Therapy and Resistance
P4-02-01 Targeting insulin receptor in estrogen receptor positive breast cancer
Cao J, Fettig LM, LaPara K, Zhang X, Murikipudi S, Delpero AR, Lancaster TM, Zion TC, Yee D. University of Minnesota, Minneapolis, MN; Akston Biosciences, Beverly, MA.
P4-02-02 The association between adiposity and anti-proliferative response to neoadjuvant endocrine therapy with letrozole in post-menopausal patients with estrogen receptor positive breast cancer
Isnaldi E, Richard F, De Schepper M, Leduc S, Maetens M, Geukens T, Van Baelen K, Nguyen H-L, Rouas G, Zoppoli G, Cardoso F, Sotiriou C, Larsimont D, Floris G, Biganzoli E, Desmedt C. KU Leuven, Department of Oncology, Laboratory for Translational Breast Cancer Research, Leuven, Belgium; Université Libre de Bruxelles, Institut Jules Bordet, J.C. Heuson Breast Cancer Translational Research Laboratory, Bruxelles, Belgium; Department of Internal Medicine and Medical Specialties, University of Genova, Ospedale Policlinico San Martino IRCCS per l’Oncologia, Genova, Italy; Champalimaud Clinical Center-Champalimaud Foundation, Breast Unit, Lisbon, Portugal; Université Libre de Bruxelles, Institut Jules Bordet, Pathology Department, Bruxelles, Belgium; KU Leuven, Department of Oncology, Laboratory for Translational Breast Cancer Research, KU Leuven, Translational Cell and Tissue Research Unit, Department of Imaging and Pathology, Leuven, Belgium; Unit of Medical Statistics, Biometry and Epidemiology, Department of Biomedical and Clinical Sciences (DIBIC) “L. Sacco” & DSRC, LITA Vialba Campus, Università degli Studi di Milano, Milano, Italy.
P4-02-03 HER1-4 protein up-regulation following short-term neoadjuvant endocrine therapy in patients with hormone receptor-positive HER2-negative breast cancer
Chaudhary LN, Jorns JM, Cheng YC, Kamaraju S, Burfeind J, Gonyo MB, Kong A, Patten C, Yen T, Cortina C, Carson E, Johnson N, Bergom C, Banerjee A, Wang Y, Sun Y, Chitambar CR, Rui H. Medical College of Wisconsin, Milwaukee, WI.
P4-02-04 Endocrine therapy treatment radiosensitizes estrogen receptor-positive breast cancers
Michmerhuizen AR, Lerner L, Pesch AM, Ward C, Schwartz R, Wilder-Romans K, Liu M, Wharram B, Harold A, Azaria R, Zambrana Garcia N, Hayes DF, Rae JM, Pierce LJ, Speers CW. University of Michigan, Ann Arbor, MI.
P4-02-05 Exploiting novel models of endocrine-resistant breast cancer to identify new therapeutic targets
Soosainathan A, Nikitorowicz-Buniak J, Pancholi S, Iravani M, Alexander J, Syed Haider S, Johnston SR, Dowsett M, Martin LA, Isacke CM. Division of Breast Cancer Research, Institute of Cancer Research, London, United Kingdom; Breast Unit, Royal Marsden Hospital, London, London, United Kingdom; The Ralph Lauren Breast Cancer Centre, Royal Marsden Hospital, London, United Kingdom.
P4-02-06 Exploiting ceramide homeostasis to target endocrine therapy-resistant breast cancer
Pal P, Millner A, Atilla-Gokcumen E, Frasor J. University of Illinois at Chicago, Chicago, IL; SUNY, Buffalo, Buffalo, NY.
P4-02-07 Lasofoxifene as a potential treatment for aromatase inhibitor resistant ER positive breast cancer
Laine M, Greene ME, Leng T, Kurleto JD, Li S, Komm B, Greene GL. University of Chicago, Chicago, IL; Komm-Sandin Pharma Consulting, Philadelphia, PA.
P4-02-08 Amcenestrant in combination with CDK4/6 inhibitor palbociclib demonstrates synergistic anti-tumor activity in ER+ endocrine-resistant breast cancer xenograft models
Shomali M, Guo Z, Cheng J, Sullivan A, El-Ahmad Y, Sun F, Sidhu S, Lee JS, Cai H, Pollard J, Debussche L, Soria C, Bouaboula M. Sanofi, Cambridge, MA; Sanofi, Vitry-sur-Seine, France.
P4-02-09 The lncRNA XIST mediates sensitivity to ERβ targeted therapies in triple negative breast cancer
Emch MJ, Aspros KGM, Bruinsma ES, Kalari KR, Jones CJ, Simone BW, Goetz MP, Hawse JR. Mayo Clinic, Rochester, MN.
P4-02-10 Pfkfb3 inhibition significantly decreases endocrine-resistant breast cancer growth and induces necroptotic cell death
Jones BC, Sengupta S, Sevigny CM, Jin L, Pohlmann PR, Shajahan-Haq A, Clarke R. Georgetown University, Washington, DC; University of Minnesota, The Hormel Institute, Austin, MN.
P4-02-11 A SIM2s/SEMA7A switch drives therapeutic resistance in ER+ breast cancer
Wyatt GL, Crump LS, Lyons TR, Porter WW. Department of Veterinary Integrative Biosciences, College of Veterinary Medicine and Biomedical Sciences, Texas A&M University, College Station, TX; Division of Medical Oncology, Department of Medicine, School of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO.
P4-02-12 Oxidative phosphorylation and NRF2 activation mediate resistance to estrogen deprivation in ER+ breast cancer
Tau S, Miller TW. Dartmouth College, Lebanon, NH.
P4-02-13 Withdrawn
P4-02-14 Breast cancer cell/adipocyte crosstalk in obesity hampers the efficacy of tamoxifen
Caruso A, Gelsomino L, La Camera G, Giordano C, Panza S, Bonofiglio D, Catalano S, Andò S, Barone I. Department of Pharmacy and Health and Nutritional Sciences, University of Calabria, Rende, Italy.
P4-02-15 Thromboembolic events (TEE) in patients with HER2-negative, hormone receptor-positive metastatic breast cancer treated with Ribociclib combined with Letrozole or Fulvestrant. Real-world data
Abdel-Razeq H, Tamimi F, Edaily S, Sharaf B, Abunasser M, Salama O, Abdel-Razeq R, Abdulelah H, Bater R. King Hussein Cancer Center, Amman, Jordan; Istishari Hospital, Amman, Jordan.
P4-02-16 Investigating the role of NRIP1 as a novel marker and therapeutic target for breast cancer
Zhu Y, Zaidi F, Rao K, Yuan R. SIU School of Medicine, Springfield, IL.
   
  Tumor Cell and Molecular Biology: Etiology/Carcinogenesis
P4-03-01 Budding Tumorigenesis: A novel proposed model for breast cancer tumorigenesis
Yaghoobi V, Aung TNWE, Moutafi M, Cooke TL, Rimm DL. Yale University, New Haven, CT; Dartmouth Geisel School of Medicine, Hanover, NH.
   
  Tumor Cell and Molecular Biology: Immunology and Preclinical Immunotherapy
P4-04-01 β2-adrenergic receptor signaling regulates metabolic pathways critical for the function of myeloid-derived suppressor cells
Mohammadpour H. Roswell Park Comprehensive Cancer Institute, Buffalo, NY
P4-04-02 A clinical-stage toll-like receptor 5 agonist, entolimod, boosts chemo-immunotherapy in pre-clinical TNBC by generating durable antitumor immunity
Brackett CM, Aldrich AR, Greene KF, Kandar B, Veith J, Burdelya LG, Abrams SI, Gudkov AV. Roswell Park Comprehensive Cancer Center, Buffalo, NY.
P4-04-03 Modulation of antitumor immunity by extracellular matrix environment in vitro
Robertson C, Sebastian A, Hinckley A, Rios-Arce N, Hynes W, He W, Hum N, Wheeler E, Coleman M, Moya M. Lawrence Livermore National Lab, Livermore, CA.
P4-04-04 APOBEC3F is expressed by immune cells and is associated with immune response and survival in triple negative breast cancer
Wu R, Oshi M, Asaoka M, Yamada A, Yan L, Endo I, Ishikawa T, Takabe K. Roswell Park Comprehensive Cancer Center, Buffalo, NY; Tokyo Medical University, Tokyo, Japan; Yokohama City University, Yokohama, Japan.
P4-04-05 Development of unique immune responses triggered by cryoablation of breast cancers
Wallon M, Klein JD, Aukers Z, Metz N, Ahudja V, Mandik-Nayak L, Ciocca V, Zemba-Palko V, Ciocca RM, Sabol JL, Carp NZ. Lankenau Institute for Medical Research, Wynnewood, PA; Lankenau Medical Center, Wynnewood, PA.
P4-04-06 Integrative analysis of single-cell transcriptomic and spatial profiles characterized distinct tumor microenvironment phenotypes in hormone receptor positive (HR+) breast cancer
Shimada K, Cui YX, Goldberg JS, Pastorello R, Davis J, Vallius T, Kania L, Patel A, Moore M, Ogayo ER, Dillon D, Sorger PK, Guerriero JL, Mittendorf EA. Harvard Medical School, Boston, MA; Dana-Farber Cancer Institute, Boston, MA; Brigham and Women's Hospital, Boston, MA.
P4-04-07 Progesterone promotes immunomodulation and tumor development in the murine mammary gland
Werner LR, Gibson KA, Goodman ML, Helm DE, Walter KR, Holloran SM, Trinca GM, Hastings RC, Yang HH, Hu Y, Wei J, Lei G, Yang X-Y, Madan R, Molinolo AA, Markiewicz MA, Chalise P, Axelrod ML, Balko JM, Hunter KW, Hartman ZC, Lange CA, Hagan CR. University of Kansas School of Medicine, Kansas City, KS; National Cancer Institute, Bethesda, MD; Duke University, Durham, NC; University of Kansas Medical Center, Kansas City, KS; University of California San Diego Moores Cancer Center, La Jolla, CA; Vanderbilt University Medical Center, Nashville, TN; University of Minnesota Cancer Center, Minneapolis, MN.
P4-04-08 Determination of PD-L1 expression on tumorspheres cultured from the peripheral blood in patients with breast cancer
Pizon M, Schott D, Pachmann U, Pachmann K. Transfusion Center Bayreuth, Bayreuth, Germany.
P4-04-09 Systematic analysis of immune cell composition revealed immunological profile of breast cancer microenvironment represented by histologically assessed tumor-infiltrating lymphocyte and PD-L1 expression
Hanamura T, Kitano S, Kagamu H, Yamashita M, Terao M, Tsuda B, Okamura T, Kumaki N, Hozumi K, Harada N, Iwamoto T, Honda C, Kurozumi S, Niikura N. Tokai University School of Medicine, Isehara, Japan; The Cancer Institute Hospital of JFCR, Koto, Ariake, Japan; Saitama Medical University International Medical Center, Hidaka, Japan; Chugai Pharmaceutical Co., Ltd., Kamakura, Japan; Okayama University Hospital, Shikata, Japan; Gunma University Graduate School of Medicine, Maebashi, Japan; International University of Health and Welfare, Narita, Japan.
P4-04-10 Pharmacological targeting of cholinergic receptors as a novel breast cancer immunotherapy
Eliceiri BP, Qian J, Blair S. UC San Diego, San Diego, CA.
P4-04-11 Dysregulation of immune checkpoint proteins in newly- diagnosed early breast cancer patients
Rapoport BL, Steel HC, Benn CA, Nayler S, Smit T, Heyman L, Theron A, Hlatswayo N, Kwofie L, Meyer P, Anderson R. Department of Immunology, Faculty of Health Sciences, University of Pretoria, Pretoria, South Africa; Head of Netcare Breast Care Centre, Johannnesburg, South Africa; Drs Gritzman & Thatcher Inc Laboratories & Wits Donald Gordon Medical Centre, Johannesburg, South Africa; The Medical Oncology Centre of Rosebank, Johannesburg, South Africa.
P4-04-12 Macrophage migration inhibitory factor regulates triple-negative breast cancer progression by enhancing the recruitment of immune suppressive cells
Charan M, Das S, Mishra S, Varikuti S, Satoskar AR, Ganju RK. The Ohio State University, Columbus, OH.
P4-04-13
S100a7/rage signaling promotes breast tumorigenesis through modulating tumor-associated macrophages

Verma AK, Wilkie T, Mishra S, Charan M, Ganju RK. Wexner Medical Center The Ohio State University, Columbus, OH.
P4-04-14 Immunological markers in patients with breast cancer occurring during pregnancy - Results from GBG BCP study
Galas K, Gleitsmann M, Rey J, Solbach C, Witzel I, Karn T, Schneeweiss A, Sinn B, Fehm T, Denkert C, Müller V, Litmeyer A-S, Schem C, Jank P, Marmé F, Furlanetto J, Fasching PA, Stickeler E, Ortmann O, van Mackelenbergh M, Nekljudova V, Loibl S. GBG and Institute of Pathology, UKGM University Hospital Marburg, Philipps-Universität, Marburg, Germany; Institute of Pathology, UKGM University Hospital Marburg, Philipps-Universität Marburg, Marburg, Germany; German Breast Group, Neu-Isenburg, Germany; Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum Frankfurt, Frankfurt, Germany; Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany; Goethe University Hospital, Frankfurt, Germany; National Center for Tumor Diseases, University Hospital and German Cancer Research Center, Heidelberg, Germany; Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt Universität zu Berlin, Department of Pathology, Berlin, Germany; Klinik für Frauenheilkunde und Geburtshilfe Universitätsklinikum Düsseldorf, Düsseldorf, Germany; Institute of Pathology, UKGM University Hospital, Philipps-Universität Marburg, Marburg, Germany; Mammazentrum Hamburg, Hamburg, Germany; Medizinische Fakultät Mannheim, Universität Heidelberg, Universitätsfrauenklinik, Mannheim, Germany; Department of Gynecology and Obstetrics, University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany; Klinik für Gynäkologie und Geburtsmedizin, Uniklinik, Aachen, Germany; Caritas-Krankenhaus St. Josef, Regensburg, Germany; Universitätsklinikum Schleswig-Holstein, Klinik für Gynäkologie und Geburtshilfe, Schleswig-Holstein, Germany; German Breast Group, Marburg, Germany.
   
  Prognostic and Predictive Factors - Prognostic Factors: Clinical Testing and Validation
P4-05-01 Results from the first UK NEQAS ICC & ISH external quality assessment for Ki-67 demonstration in breast cancer
Dodson A, Wilkinson D, Dowsett M, Parry S. UK NEQAS ICC & ISH, London, United Kingdom.
P4-05-02 Impact of hormone receptor status on clinicopathological characteristics and outcomes among HER2-positive metastatic breast cancer patients in the ESME database
Cabel L, Carton M, Dieras V, Petit T, Guiu S, Veyret C, Goncalves A, Uwer L, Augereau P, Ferrero J-M, Levy C, Dalenc F, Desmoulins I, Mouret-Reynier MA, Debled M, Bachelot T, Eymard J-C, Pistilli B, Jean Frenel JS, Chevrot M, Mailliez A, Carausu M. Curie, Saint Cloud, France; Centre Eugène Marquis, Rennes, France; Centre Paul Strauss/ICANS, Saint Cloud, France; Institut Régional du Cancer Montpellier / Val d’Aurelle, Montpellier, France; Centre Henri Becquerel, Rouen, France; Institut Paoli Calmettes, Marseille, France; Institut de Cancérologie de Lorraine, Nancy, France; Institut de Cancérologie de l'Ouest - Paul Papin, Angers, France; Centre Antoine Lacassagne, Nice, France; Centre François Baclesse, Caen, France; Institut Claudius Regaud, Toulouse, France; Centre Georges-François Leclerc, Dijon, France; Centre Jean Perrin, Clermond Ferrand, France; Institut Bergonié, Bordeaux, France; Centre Léon Bérard, Lyon, France; Institut Jean Godinot, Reims, France; Gustave Roussy, Villejuif, France; Institut de Cancérologie de l'Ouest - René Gauducheau, Nantes, France; Unicancer, Paris, France20Centre Oscar Lambret, Lille, France.
P4-05-03 Evaluation of the prognostic accuracy of SimBioSys TumorScope in early breast cancer
Howard FM, He G, Pfeiffer JR, Peterson JR, Cole JA, Pearson AT, Abe H, Nanda R. University of Chicago, Chicago, IL; SimBioSys, Chicago, IL.
P4-05-04 Menopausal breast cancer: Bone mineral density (BMD) and prognostic factors
Izquierdo M, Baulies S, Ara C, Garcia M, Fargas F, Tresserra F, Fabregas R, Ubeda A, Barri S P. Hospital Universitario Dexeus, Barcelona, Spain.
P4-05-06
High absolute lymphocyte counts are associated with longer overall survival in patients with metastatic breast cancer treated with eribulin as the first-line chemotherpy. Combined analysis of two phase 2 study

Takashima T, Kimura K, Kawajiri H, Kashiwagi S, Tokunaga S, Nishimura S, Noda S, Oku H, Ikari A, Tominaga T, Maezawa S, Sakane J, Iwamoto M. Osaka City Univeresity Graduate School of Medicine, Osaka, Japan; Osaka Medical and Pharmaceutical University, Takatsuki, Japan; Ishikiri Seiki Hospital, Higashi Osaka, Japan; Osaka City University Graduate Scoolo of Medicine, Osaka, Japan; Osaka City General Hospital, Osaka, Japan; Sumitomo Hospital, Osaka, Japan.
P4-05-07 Assistance with an artificial intelligence-powered tumor infiltrating lymphocytes (TIL) analyzer reduces interobserver variation in pathologic scoring of TIL in breast cancer
Cho SI, Jung W, Choi S, Kim S, Song S, Park G, Ma M, Park S, Pereira S, Ahn S, Aum BJ, Shin S, Paeng K, Yoo D, Ock C-Y. Lunit, Seoul, Republic of Korea; Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea; Ajou University School of Medicine, Suwon, Republic of Korea.
P4-05-08 18F-FDG uptake of visceral adipose tissue on preoperative PET/CT as a predictive marker for breast cancer recurrence
Yoon CI, Kim HJ, Cha YJ, Kim D, Bae SJ, Ahn SG, Jeong J, Park W-C, Ryu YH, Jeon TJ, Paik PS, Kim CW. St Mary's Hospital, Seoul, Seoul, Republic of Korea; Department of Nuclear Medicine, Yongin Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea; Department of Pathology, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea; Department of Surgery, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea; Department of Nuclear Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea.
P4-05-09
Clinicopathologic characteristics and molecular profiling of HER2-low breast cancer: A single academic institution experience

Zhang H, Katerji H, Turner BM, Hicks DG. University of Rochester Medical Center, Rochester, NY.
P4-05-10 Composite score combining multi-gene testing with liquid biopsy may have stronger prognostic value in HR+/HER2- breast cancer
Bilani N, Yaghi M, Saravia D, Jabbal I, Bou Zerdan M, Elson L, Liang H, Nahleh Z. Icahn School of Medicine, Mount Sinai Morningside and West, New York, NY; Cleveland Clinic Florida, Weston, FL.
P4-05-11 The clinical importance of the new category, ER low-positive in the ER expression HER2 negative early breast cancer
Wakako T. National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan.
P4-05-12
Kinetics of endocan in the peripheral blood before and after the resection of primary breast tumors

Daiki K, Kanada Y, Nagata A, Nakamura S, Kato Y. Hoshi University School of Pharmacy and Pharmaceutical Sciences, Tokyo, Japan; Tokyo Rosai Hospital, Tokyo, Japan; Showa University School of Medicine, Tokyo, Japan.
P4-05-13
Prognostic implication of Yin Yang 1 (YY1) overexpression in patients with primary breast cancer

Cha C, Park H, Kim CG, Chung MS. Hanyang University Seoul Hospital, Seoul, Republic of Korea; Hanyang University, Seoul, Republic of Korea.
P4-05-14
Validation of PREDICT version 2.2 on a retrospective cohort of Indian women with operable breast cancer

Kothari B, Nair N, Kannan S, Hawaldar R, Parmar V, Siddique S, Vanmali V, Tondare A, Chitkara G, Thakkar P, Shet T, Joshi S, Badwe R. Tata Memorial Hospital, Mumbai, India.
P4-05-15 Follow-up of prospective cohort of Mexican premenopausal women with breast cancer who received guided adjuvant treatment with the EndoPredict assay
Vazquez-Juarez D, Vaca-Cartagena BF, Becerril-Gaitan A, Deneken-Hernandez Z, Ferrigno AS, Maffuz-Aziz A, Lopez-Martinez EA, Barragan-Carrillo R, Muñoz-Lozano JF, Villarreal-Garza C. Breast Cancer Center, Hospital Zambrano Hellion TecSalud, Tecnologico de Monterrey, San Pedro Garza Garcia, Mexico; Fundacion de Cancer de Mama (FUCAM), CDMX, Mexico.
   
  Prognostic and Predictive Factors - Prognostic Factors: Index Scores
P4-06-01 OncotypeDX testing does not appear to benefit patients with grade 1, progesterone receptor positive breast cancers: A TAILORx validated study
Lee Y, W. Mylander C, Martin T, Rosman M, Sanders TJ, Sibia US, Tafra L, Jackson RS. Luminis Health Anne Arundel Medical Center, Annapolis, MD.
P4-06-02 Clinically feasible pharmacokinetic model of dynamic contrast-enhanced MRI is prognostic of recurrence free survival in breast cancer patients treated with neoadjuvant therapy
Peterson JR, Earnest TM, Huang W, Abe H, Cole, Jr, JA. SimBioSys, Inc., Champaign, IL; Advanced Imaging Research Center, Oregon Health and Science University, Portland, OR; Department of Radiology, University of Chicago, Chicago, IL.
P4-06-03 Clinical-risk assessment of ER positive, Her2 negative breast cancer patients: Correlation between the average modified magee score and mammaprint
Katerji H, Zhang H, Hicks D, Turner BM. University of Rochester, Rochester, NY.
P4-06-04 The role of axillary lymph node status in residual cancer burden calculation of triple negative breast cancer post-neoadjuvant cytotoxic chemotherapy
Gandhi S, Attwood K, Ji W, Aljabab S, Khoury T. Roswell Park Comprehensive Cancer Center, Buffalo, NY.
P4-06-05 Can we adapt neoadjuvant rectal (NAR) score besides sytemic immun inflammation index (SII) and prognostic nutritional index (PNI) as prognostic factors to locally advanced breast cancer?
Yüksel C, Doğan M, Çulcu S, Doğan L. SBU Ankara Oncology Training and Research Hospital, Ankara, Turkey.
P4-06-06

Role of lymphatic SEC62 expression in prediction of treatment response in patients undergoing neoadjuvant chemotherapy for primary breast cancer


Zimmermann J, Jung A, Doerk M, Kasoha M, Linxweiler B, Linxweiler M, Wagner M, Bohle R, Radosa M, Solomayer E, Radosa JC. Saarland University, Homburg, Germany; Klinikum Bremen Nord, Bremen, Germany.
P4-06-07 Clinical risk-assessment, risk-stratification, and outcomes of ER positive, HER2 negative breast cancer patients using the Rochester modified Magee algorithm (RoMMA)
Numbere N, Moisini I, Dhakal A, Skinner K, Shayne M, Sanders MAG, Zhang H, Hicks D, Turner BM. University of Rochester Medical Center, Rochester, NY; M. Health Fairview Ridges, Burnsville, MN; University of Louisville, Louisville, KY.
P4-06-08 Consensus on the utility of breast cancer multigene signatures in routine clinical practice among European breast cancer specialists - 1st results of the PROCURE project
Curigliano G, Cardoso F, Gnant M, Harbeck N, King J, Laenkholm A-V, Penault-Llorca F, Prat A. European Institute of Oncology, Milano, Italy; Champalimaud Clinical Centre, Lisbon, Portugal; Medical University of Vienna, Vienna, Austria; LMU University Hospital, Munich, Germany; Royal Free Hospital NHS Foundation Trust, London, United Kingdom; Zealand University Hospital, Roskilde, Denmark; Jean Perrin Center, Clermont-Auvergne University, Clermont-Ferrand, France; Hospital Clínic de Barcelona, Barcelona, Spain.
P4-06-09
Prediction of oncotype DX recurrence score by patho-biologic variables and three surrogate models

Geradts J, Kousar A, Wong J, Vohra N, Muzaffar M, Mohamed A. East Carolina University Brody School of Medicine, Greenville, NC.
   
  Prognostic and Predictive Factors - Prognostic Factors: Other
P4-07-01 Loss of HER2 on residual disease after neoadjuvant therapy in HER2-positive early breast cancer: Clinicopathological characteristics and association with outcomes
Morganti S, Marra A, Viale G, Zagami P, Sajjadi E, Corti C, Curigliano G, Fusco N, Criscitiello C. IRCCS European Institute of Oncology, Milan, Italy; Memorial Sloan Kettering Cancer Center, New York, NY; IRCCS San Raffaele Hospital, Milan, Italy.
P4-07-02 Tumor microenvironment characteristics and prognosis in breast cancer during pregnancy: The role of differentially expressed immune-related genes
Fusco N, Sajjadi E, Venetis K, Buonomo B, Blundo C, Giroda M, Di Loreto E, Scarfone G, Ferrero S, Veronesi P, Galimberti VE, Barberis M, Viale G, Guerini-Rocco E, Peccatori FA. European Institute of Oncology (IEO), Milano, Italy; Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico, Milano, Italy.
P4-07-03 Development of prognostic models based on clinical, immune-related and proliferation factors in early breast cancer patients treated with neoadjuvant chemotherapy
Garcia-Torralba E, Álvarez-Abril B, Bravo-Pérez C, Navarro Manzano E, de la Morena Barrio P, Ivars Rubio A, García-Garre E, Marín Zafra G, Ayala de la Peña F, García-Martínez E. Hospital General Universitario Morales Meseguer, Murcia, Spain.
P4-07-04 Bc cancer ipsilateral breast tumor recurrence (BCC IBTR) nomogram
Narinesingh D, Nichol A, Truong P, Gondara L, Speers C, Kugathasan L, Lohrisch C, Voduc D, Lalani N. BC Cancer, Vancouver, BC, Canada; BC Cancer, Victoria, BC, Canada; Breast and GI Outcomes Unit, BC Cancer, Vancouver, BC, Canada; University of British Columbia, Vancouver, BC, Canada.
P4-07-05 Tumor mutational profiles of extreme long-term survivors with metastatic breast cancer
Hu Y, Shin J, Roy S, Burkard ME. University of Wisconsin-Madison, Madison, WI.
P4-07-06 Circulating lipids and breast cancer survival in the Malmö diet and cancer study
Harborg S, Ahern TP, Feldt M, Rosendahl AH, Cronin-Fenton D, Melander O, Borgquist S. Aarhus University Hospital, Aarhus, Denmark; University of Vermont, Burlington, VT; Lund University, Lund, Sweden; Aarhus University, Aarhus, Denmark; Lund University, Malmö, Sweden.
P4-07-07 Metaplastic carcinoma of the breast has comparable prognosis to non-metaplastic triple negative breast cancer despite poor response to chemotherapy
Lim C, Kim J-i, Han Y, Cheun J-h, Jung JG, Kim HK, Moon H-G, Han W, Lee H-B. Seoul National University College of Medicine, Seoul, Republic of Korea.
P4-07-08 Prognostic value of intrinsic subtypes (IS) in hormone receptor-positive (HoR+) metastatic breast cancer (MBC): A systematic review and meta-analysis of prospective trials
Schettini F, Martínez-Sáez O, Chic N, Brasó-Maristany F, Galván P, Martínez D, Paré L, Vidal M, Adamo B, Muñoz M, Pascual T, Ciruelos E, Perou CM, Carey LA, Prat A. August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain; Hospital Clinic of Barcelona, Barcelona, Spain; SOLTI Innovative Cancer Research, Barcelona, Spain; Hospital 12 de Octubre, Madrid, Spain; UNC Chapel Hill, Chapel Hill, NC.
P4-07-09 Triple negative breast cancer: An analysis of the subtypes and the effects of menopausal status on invasive breast cancer
Arima H, Nishimura R, Osako T, Okumura Y, Nakano M, Fujisue M, Otsuka H. Kumamoto Shinto General Hospital, Kumamoto, Japan.
P4-07-10 Patient profiles, management and treatment patterns in HR+, HER2- early breast cancer in a real-world setting in Spain
Martín M, García Sáenz JÁ, Blancas I, Molero A, Atienza M, Cervera JM, Brown J, Rider A, Williams R, Alba E. General University Hospital Gregorio Marañón, Madrid, Spain; San Carlos Clinical Hospital, Madrid, Spain; San Cecilio Clinical Hospital, Granada, Spain; Eli Lilly and company, Madrid, Spain; Eli Lilly and company, Indianapolis, IN; Adelphi Real World, Bollington, United Kingdom; Virgen de la Victoria University Clinical hospital, Málaga, Spain.
P4-07-11 Prognostic significance of changes in tumor infiltrating lymphocytes and neutrophil-to-lymphocyte ratio after neoadjuvant chemotherapy in early breast cancer patients
Garcia-Torralba E, Álvarez-Abril B, Bravo-Pérez C, Navarro Manzano E, de la Morena Barrio P, Ivars Rubio A, García-Garre E, Marín Zafra G, Ayala de la Peña F, García-Martínez E. Hospital General Universitario Morales Meseguer, Murcia, Spain.
P4-07-12 An evaluation of lymphovascular invasion in relation to biology and prognosis according to subtypes in invasive breast cancer
Nishimura R, Osako T, Okumura Y, Nakano M, Otsuka H, Fujisue M, Arima N. Kumamoto Shinto General Hospital, Kumamoto City, Japan.
P4-07-13
An exploratory case-control study of perineural invasion in breast cancer


Cox SE, Bassett R, Yi M, Sahin A, Teshome M, Hunt K, Akay C. MD Anderson Cancer Center, Houston, TX.
P4-07-14 Long-term prognosis of minimal residual disease in breast cancer patients with breast or nodal pathologic complete response (pCR) after neoadjuvant chemotherapy (NAC)
Jieon Go, Ahn JH, Park JM, Choi SB, Kim JY, Park HS, Kim SI, Park B-W, Park S. Yonsei University College of Medicine, Seoul, Republic of Korea.
P4-07-15 Tumor infiltrating lymphocytes as a prognostic factor
Schüler K, Bethmann D, Lantzsch T, Uleer C, Hanf V, Peschel S, John J, Pöhler M, Buchmann J, Buerrig K-F, Weigert E, Kantelhardt EJ, Thomssen C, Vetter M. Dept. of Gynecology, Martin Luther University Halle-Wittenberg, Halle (Saale), Germany; Institut of Pathology, Martin Luther University Halle-Wittenberg, Halle (Saale), Germany; Dept. of Gynecology, Hospital St. Elisabeth and St. Barbara, Halle (Saale), Germany; Gynäkologische-Onkologische Praxis Uleer, Hildesheim, Germany; Dept. of Gynecology and Obstetrics, Nathanstift, Hospital Fuerth, Fürth, Germany; Dept. of Gynecology, St. Bernward Hospital Hildesheim, Hildesheim, Germany; Dept. of Gynecology, Helios Hospital Hildesheim, Hildesheim, Germany; Dept. of Gynecology, Hospital Wolfenbuettel, Wolfenbuettel, Germany; Institute of Pathology, Hospital Martha-Maria, Halle (Saale), Germany; Institute of Pathology Hildesheim, Hildesheim, Germany; Gemeinschaftspraxis Pathologie Amberg, Amberg, Germany.
P4-07-16 Correlation of Trop-2 expression with clinicopathological characteristics and outcome in triple-negative breast cancer (TNBC)
Izci H, Punie K, Waumans L, Laenen A, Wildiers H, Verdoodt3 F, Desmedt C, Ardui J, Smeets A, Han S, Nevelsteen I, Neven P, Floris G. KU Leuven, Leuven, Belgium; UZ Leuven, Leuven, Belgium; Belgian Cancer Registry, Brussels, Belgium.
P4-07-17 Association between plasma-based sequential windowed acquisition mass spectrometry (SWATH-MS) and invasive disease free survival (iDFS) in HR+/HER2- early breast cancer in the CANTO cohort
Della Noce A, Christodoulidis S, Di Meglio A, Havas J, Tran-Dien A, André F, Vaz-Luis I, Cournède P-H, Michiels S. Institut Gustave Roussy, Villejuif, France; Université Paris-Saclay, CentraleSupélec, Gif-sur-Yvette, France.
P4-07-18
Withdrawn

P4-07-19 Quantifying epithelial-mesenchymal tumor heterogeneity for prediction of patient prognosis based on EMT state
Brown MS, Abdollahi B, Ognjenovic N, Muller KE, Hassanpour S, Pattabiraman DR. Dartmouth College, Lebanon, NH; Dartmouth Hitchcock Medical Center, Lebanon, NH.
P4-07-20 Survival analysis using the entire transcriptome to pinpoint biomarkers with the highest prognostic power
Gyorffy B. TTK, Budapest, Hungary.
P4-07-21

High Tinagl1 expression is a marker of good prognosis in breast cancer


Kato A, Kondo N, Wanifuchi-Endo Y, Fujita T, Asano T, Hisada T, Uemoto Y, Terada M, Toyama T. Nagoya City University, Nagoya-shi, Mizuho-ku, Japan.
P4-07-22 Evaluation of human epididymis protein 4 serum and tissue expression in ductal carcinoma in situ of the breast
Leee JS, Kim NI, Park MH. Chonnam National University Hwasun Hospital, Jeollanam-do, Republic of Korea.
P4-07-23
Piezo1 is associated with worse prognosis along with promoted epithelial-mesenchymal transition and hypoxia as well as less anti-cancer immune cells in hormone receptor (HR)-negative breast cancer

Katsuta E, Takabe K, Opyrchal M. Roswell Park Comprehensive Cancer Center, Buffalo, NY; Washington University School of Medicine, St. Louis, MO.
P4-07-24 High Mammographic Breast density was correlated with overall survival of operable breast cancer which expressed CD44+CD24-/ALDH-1+
Lee J, Kim W-G. Inje University, Busan, Republic of Republic.
P4-07-25 Distant metastasis of breast cancer is triggered by changes in the dynamics of metastatic cells after removal of the primary lesion
Tokisawa H, Aruga T, Honda Y, Ishiba T, Yonekura R, Iwamoto N, Kumaki Y. Tokyo Metropolitan Cancer and Infectious Disease Center Komagome Hospital, Tokyo, Japan.
P4-07-26 Clinical impact of tumor infiltrating lymphocytes and neutrophil-lymphocyte ratio in estrogen receptor-positive/HER2-negative breast cancer patients with high 21-gene signature recurrence scores
Kanaoka H, Nagahashi M, Ishikawa E, Bun A, Fukui R, Ozawa H, Higuchi T, Natori K, Imamura M, Takatsuka Y, Miyoshi Y. Hyogo College of Medicine, Nishinomiya, Japan.
P4-07-27
De novo metastatic breast cancer; clinical characteristics and treatment outcomes in a developing country

Almasri H, Erjan A, Abudawaba H, Ashouri K, Mheid S, Alnsour A, Abdel-Razeq H. King Hussein Cancer Center, Amman, Jordan.
P4-07-28 Early relapse and predictors of relapse-free survival in neoadjuvant chemotherapy-treated breast cancer patients
Martin N, Pasztorova J, Hibell I, Wheatley D. University of Exeter, Exeter, United Kingdom; Royal Cornwall Hospital, Truro, United Kingdom.
P4-07-29 Reactive Oxygen Species (ROS) pathway is associated with aggressive cancer biology, elevated immune response, and with worse survival in ER-positive/HER2-negative breast cancer
Oshi M, Wu R, Yamada A, Yan L, Ishikawa T, Endo I, Takabe K. Roswell Park Comprehensive Cancer Institute, Buffalo, NY; Yokohama City University Graduate School of Medicine, Yokohama, Japan; Tokyo Medical University, Tokyo, Japan.
P4-07-30 Residual lymphovascular invasion: Predicts the outcome of neoadjuvant chemotherapy in locally advanced breast cancer
Elemam O, Elnaghi K, Emarah A, Alghanami H, Abdelkhalek S. King Abdullah Medical City KSA ,Mansoura University Oncology Center Egypt, Makkah, Saudi Arabia; King Abdullah Medical City KSA ,Mansoura University Oncology Center Egypt, Makkah, Saudi Arabia; King Abdullah Medical City, Makkah, Saudi Arabia; King Abdullah Medical City KSA, Mansoura University Radiotherapy Department Egypt, Makkah, Saudi Arabia.
P4-07-31 Racial disparities in breast cancer chiefly reside in the lesser-known quadruple-negative breast cancer
Bhattarai S, Saini G, Rupji M, Luningham J, Turaga RC, Krishnamurti U, Li X, Agboola J, Abubakar M, Nggada HA, Omonisi A, Ahmed SA, Cavalli L, Aneja R. Department of Biology, Georgia State University, Atlanta, GA; Department of Biostatistics and Bioinformatics Shared Resource, Winship Cancer Institute, Emory University, Atlanta, GA; Department of Population Health Sciences, Georgia State University School of Public Health, Atlanta, GA; Department of Pathology and Laboratory Medicine, Emory University, Atlanta, GA; Department of Pathology, Emory University School of Medicine, Atlanta, GA; Morbid Anatomy and Histopathology Department, Olabisi Onabanjo University, Ogun, Nigeria; Department of Pathology, Ahmadu Bello University, Zaria, Nigeria; Department of Histopathology, University of Maiduguri, Maiduguri, Nigeria; Department of Anatomic Pathology, Ekiti State University, Ado-Ekiti, Nigeria; Research Institute Pelé Pequeno Príncipe, Curitiba, Brazil.
P4-07-32
Mammaprint and Blueprint are prognostic of outcome following neoadjuvant chemotherapy


Chung AP, Srour M, Dadmanesh F, Kim S, Giuliano A, Wei J, Huynh Y, Wang S, Menicucci A, Audeh S. Division of Surgical Oncology, Department of Surgery, Cedars-Sinai Medical Center, Los Angeles, CA; Biostatistics Core, Cedars-Sinai Medical Center, Los Angeles, CA; Agendia Inc., Irvine, CA.
   
  Psychosocial, QOL, and Educational Aspects - QOL Issues : Palliation and Pain Management
P4-08-01 Effectiveness of electroacupuncture versus auricular acupuncture in breast cancer survivors with chronic musculoskeletal pain: The PEACE randomized clinical trial
Zhi WI, Mao JJ, Baser RE, Li SQ, Blinder VS, Norton L, Seidman AD, Robson ME, Bao T. Memorial Sloan Ketter Cancer Center, Breast Medicine Service, New York, NY; Memorial Sloan Ketter Cancer Center, Integrative Medicine Service, New York, NY; Memorial Sloan Ketter Cancer Center, Epidemiology & Biostatistics, New York, NY.
   
  Psychosocial, QOL, and Educational Aspects - QOL Issues: Psychosocial Aspects
P4-09-01 Incidence of patient-reported fatigue developing in patients receiving palbociclib and endocrine therapy for advanced HR+ HER2- breast cancer
Rahman SA, Erica L Mayer EL, Poort H, Schrag D, Tung SC, Zhou ES, Wiley A, Finkelstein L, Elguenaoui E, Nolan M, Joffe H,. Brigham and Women's Hospital/Harvard Medical School, Boston, MA; Dana-Farber Cancer Institute/Harvard Medical School, Boston, MA; Dana-Farber Cancer Institute, Boston, MA; Brigham and Women's Hospital, Boston, MA.
P4-09-02
The impact of breast conserving surgery re-excision on patient-reported outcomes using the BREAST-Q


Matar R, Flanagan M, Fuzesi S, Haglich K, Yin S, Sevilimedu V, Nelson J, Gemignani ML. Memorial Sloan Kettering Cancer Center, New York, NY; University of Washington, Seattle, WA; NewYork-Presbyterian/Columbia University Irving Medical Center, New York, NY
P4-09-03
Factors affecting the parenting stress and depression in young women with breast cancer

Shin Y, Kim H, Kim S, Lee SB, Kim J, Chung IY, Ko BS, Lee JW, Son BH, Ahn SH, Kim H-w, Kim HJ. Asan Medical Center, Seoul, Republic of Korea.
p4-09-04 When discussing breast reconstruction, do psychosocial characteristics influence which surgical options patients remember?
Wang H, Liu J, Bordes MC, Chopra D, Reece GP, Markey MK, Hoffman AS. The University of Texas at Austin, Austin, TX; The University of Texas MD Anderson Cancer Center, Houston, TX.
P4-09-05 Focus on non-adherence: A qualitative exploration of perceptions associated to adjuvant endocrine therapy (ET) in premenopausal patients with breast cancer and their health care providers (HCP)
Fasse LM, Roche N, Boinon D, Menvielle G, Dumas A, Rivera S, Matias M, Di-Meglio A, Delaloge S, Vaz-Luis I, Pistilli B. Gustave Roussy; LPPS (UR 4057), University of Paris, Villejuif, Paris, France; Gustave Roussy, Villejuif, France; IPLESP Inserm - Sorbonne Université, Paris, France.
P4-09-06
An investigation into the presence of posttraumatic stress disorder symptoms in breast cancer patients


Guidry ET, Jahan N, Jones C. UMC Cancer Center, Lubbock, TX; Texas Tech Health Science Center, Lubbock, TX.
P4-09-07 Psychological impact of type of breast cancer surgery: A national cohort study
Ahn SK, Oh S, Kim J, Choi J-S, Hwang K-T. Kangnam Sacred Heart Hospital, Seoul, Republic of Korea; Seoul Metropolitan Government-Seoul National University Boramae Medical Center, Seoul, Republic of Korea.
P4-09-08
Examining neurocognitive function in breast-cancer patients after chemotherapy


Sharpe J, Palettas M, Grimm M, Kassem M, Ramaswamy B, Wesolowski R, Williams N, Sardesai S, Stover D, VanDeusen J, Cherian M, Pariser A, Gatti-Mays M, Lustberg M, Boxley L. The Ohio State University Internal Medicine, Columbus, OH; The Ohio State University Center for Biostatistics, Columbus, OH; The Ohio State University Comprehensive Cancer Center, Columbus, OH; The Ohio State University Department of Psychiatry and Behavioral Health, Columbus, OH.
P4-09-09 Internationalization of the Amsterdam cognition scan: A validated set of online cognitive tests for (neuro-)oncological studies
Lee Meeuw Kjoe P, van der Wall E, Schagen S. Netherlands Cancer Institute, Amsterdam, Netherlands; University Medical Center Utrecht, Utrecht, Netherlands.
   
  Psychosocial, QOL, and Educational Aspects: QOL - Supportive Care
P4-10-01
Quality of life and symptom severity in the PALLAS randomized trial of palbociclib with adjuvant endocrine therapy in early breast cancer (AFT-05)

Naughton MJ, Zahrieh D, Gnant M, Zdenkowski N, Lemieux J, Mao JJ, Bjelic-Radisic V, Shinn E, Balic M, Thomssen C, Neisel J, Ruiz-Echarri M, Loibl S, Isaacs C, Cameron D, Carrasco FMH, Goetz M, Wette V, Werutsky G, Rugo H, Vetter M, Tseng L-M, Miller K, Fitzal F, Gil Gil JM, Park H, Linderholm B, Bajetta E, Dayao Z, Prat A, Ehrhardt K, Metzger O, Arahmani A, Law E, Partridge A, Carey L, Zoroufy A, Dueck A, Hlauschek D, DeMichele A, Mayer E. Ohio State University, Columbus, OH; Mayo Clinic, Rochester, MN; Medical University of Vienna, Vienna, Austria; Calvary Mater Newcastle, Waratah, Australia; Center Hospitalier Universitaire de Quebec, Universite Laval, Quebec City, QC, Canada; Memorial Sloan Kettering Cancer Center, New York City, NY; University Hospital Helios, Wuppertal, Germany; MD Anderson Cancer Center, Houston, TX; Medical University Graz, Graz, Austria; Universitatsfrauenklinik-Halle, Wittenberg, Germany; Emery University, Atlanta, GA; European Medical Center, Moscow, Russian Federation; German Breast Group, Neu-Isenburg, Germany; Georgetown University, Georgetown, DC; Cancer Research UK Edinburgh Center, Edinburgh, United Kingdom; Hospital Virgen Macarena Sevilla, Sevilla, Spain; Breast Centre, Sank Veit an der Glan, Austria; Latin American Cooperative Oncology Group (LACOG), Porto Alegre, Brazil; University of California, San Francisco, CA; University Hospital Basel, Basel, Switzerland; Tapei Veterans General Hospital, Tapei, Taiwan; Indiana University Simon Cancer Center, Indianapolis, IN; Catalan Institute of Oncology, Barcelona, Spain; Washington University, St. Louis, MO; Karolinska Institute, Solna, Sweden; Institute of Oncology, Polyclinic Hospital, di Monza, Italy; University of New Mexico Hospital, Albuquerque, NM;; Hospital Clinic, Barcelona, Spain; Austrian Breast and Colorectal Cancer Study Group (ABCSG), Vienna, Austria; Dana Farber Cancer Institute/Alliance, Boston, MA; Breast International Group, Brussels, Belgium; Pfizer, Inc., New York City, NY; University of North Carolina, Chapel Hill, NC; Mayo Clinic/Alliance, Rochester, MN; Mayo Clinic/Alliance, Phoenix, AZ; Austrian Breast Cancer Study Group (ABCSG), Vienna, Austria; University of Pennsylvania, Philadelphia, PA; Dana Farber Cancer Institute, Boston, MA.
P4-10-02 Patient-reported outcomes in EA1131: A randomized phase III trial of platinum vs. capecitabine in patients with residual triple-negative breast cancer after neoadjuvant chemotherapy
Smith KL, Zhao F, Mayer IA, Tevaarwerk AJ, Garcia SF, Arteaga CL, Symmans WF, Park BH, Burnette BL, Makower DF, Block M, Morley KA, Jani CR, Mescher C, Dewani SJ, Brown-Glaberman U, Flaum LE, Mayer EL, Sikov WM, Rodler ET, DeMichele AM, Sparano JA, Wolff AC, Miller KD, Wagner LI. Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD; Dana Farber Cancer Institute, ECOG-ACRIN Biostatistics Center, Boston, MA; Vanderbilt University Medical Center, Vanderbilt-Ingram Cancer Center, Nashville, TN; University of Wisconsin Carbone Cancer Center, Madison, WI; Northwestern University, Evanston, IL; UT Southwestern Simmons Cancer Center, Dallas, TX; MD Anderson Cancer Center, Houston, TX; Cancer Research of Wisconsin and Northern Michigan (CROWN) NCORP, Green Bay, WI; Montefiore Medical Center, New York, NY; Alegent Health Bergan Mercy Medical Center, Omaha, NE; Saint Joseph Mercy Hospital, Ann Arbor, MI; Phoebe Putney Memorial Hospital, Albany, GA; Metro-Minnesota Community Oncology Research Consortium, St. Louis Park, MN; Columbus Oncology and Hematology Associates Inc., Columbus, OH; University of New Mexico Comprehensive Cancer Center, Albuquerque, NM; Dana-Farber Cancer Institute, Boston, MA; Women and Infants Hospital of Rhode Island, Providence, RI; University of California, Davis, Davis, CA; University of Pennsylvania/Abramson Cancer Center, Philadelphia, PA; Montefiore Medical Center, Bronx, NY; Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, IN; Wake Forest University Health Sciences, Winston-Salem, NC.
P4-10-03
Immunogenicity of SARS-CoV-2 vaccination in subjects on active treatment for breast cancer

Bivona C, Li K, Sharma P, He J, Martin G, Godwin AK, Rooney A, Williamson S, Doolittle G, Sun W, Kimler BF, O'Dea AP, Nye LE, McGuirk JP, Pessetto Z, Haney LH, Balmaceda N, Mitchell L, Finke K, Nelson M, Pal Mudaranthakam D, Streeter N, Lafaver S, Heldstab J, Khan QJ. University of Kansas Health System, Westwood, KS; University of School of Medicine, Kansas City, KS; University of Kansas Medical Center, Kansas City, KS; University of Kansas Cancer Center, Westwood, KS; Sinochips Diagnostics, Olathe, KS; University of Kansas Medical Center, Westwood, KS.
P4-10-04 Health-related quality of life (HRQoL) in hormone receptor-positive, HER2-negative, luminal B breast cancer patients treated with ribociclib plus letrozole or chemotherapy
Villacampa G, Paré L, Hernando C, Arumí M, Muñoz M, Gil-Gil M, Izarzugaza Y, Ferrer N, Montaño A, Ciruelos E, González-Santiago S, Falato C, Villagrasa P, Gavilá J, Prat A, Pascual T. SOLTI Breast Cancer Research Group / Oncology Data Science, Vall d'Hebron Institute of Oncology (VHIO), Barcelona / Barcelona, Spain; SOLTI Breast Cancer Research Group, Barcelona, Spain; Department of Medical Oncology, Hospital Clínico Universitario of Valencia, Valencia, Spain; Department of Medical Oncology, Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology, Barcelona, Spain; SOLTI Breast Cancer Research Group / Department of Medical Oncology, Hospital Clinic of Barcelona, Barcelona / Barcelona, Spain; Department of Medical Oncology, Institut Català d'Oncologia Hospitalet, Hospitalet de Llobregat, Spain; Department of Medical Oncology, Hospital Universitario Fundación Jimenez Díaz, Madrid, Spain; Department of Medical Oncology, Hospital Universitari Son Espases, Palma de Mallorca, Spain; Department of Medical Oncology, Hospital Universitario Virgen del Rocío, Sevilla, Spain; SOLTI Breast Cancer Research Group / Hospital Universitario 12 de Octubre / Centro Integral Oncológico Clara Campal HM (CIOCC), Barcelona / Madrid / Madrid, Spain; Department of Medical Oncology, Hospital Universitario San Pedro de Alcántara, Cáceres, Spain; SOLTI Breast Cancer Research Group / Translational Genomics and Targeted Therapeutics in Solid Tumors, August Pi i Sunyer Biomedical Research Institute, Barcelona / Barcelona, Spain; Department of Medical Oncology, Instituto Valenciano de Oncología, Valencia, Spain; SOLTI Breast Cancer Research Group / Department of Medical Oncology, Hospital Clinic of Barcelona / Translational Genomics and Targeted Therapeutics in Solid Tumors, August Pi i Sunyer Biomedical Research Institute / Department of Medicine, University of, Barcelona / Barcelona / Barcelona / Barcelona, Spain.
P4-10-05 Safety and efficacy of low dose topical testosterone for sexual function improvement in women with breast cancer under treatment with ovarian suppression and aromatase inhibitor
Taranto P, de Brito Sales D, de Melo Pompei L, Leal A, Schvartsman G, Buzaid AC. Hospital Israelita Albert Einstein, São Paulo, Brazil; Hospital Orium, Goiania, Brazil; Faculdade de Medicina do ABC, São Paulo, Brazil; Hospital BP- A Beneficiência Portuguesa de São Paulo, São Paulo, Brazil.
P4-10-06 Best quality care from a distance (BQual-D): Maintaining high quality care for hormone receptor positive (HR+) metastatic breast cancer (MBC) during the COVID pandemic, description of the program and provider satisfaction
Kimmick G, Davakaran S, Moore H, Rose C, Gentry P, Willis M, Dent S, Sammons S, Force J, Westbrook K, Anders C,Shelby R. Duke University Medical Center, Durham, NC.
P4-10-07
It is possible to achieve the same benefits in online models than in face to face programs in bc patients

Castellanos Montealegre M, Gil-Herrero L, Casla-Barrio S. Spanish Cancer Association, Alcázar de San Juan (Ciudad Real), Spain; Spanish Cancer Association, Segovia, Spain; Spanish Cancer Association, Madrid, Spain.
P4-10-08
Characterizing cannabidiol use in a breast cancer population

Grogan N,Henry NL. University of Michigan, Ann Arbor, MI.
P4-10-09 Patient-centered dosing: Oncologists’ perspectives about treatment-related side effects and individualized dosing for patients with metastatic breast cancer (MBC)
Loeser AL, Bardia A, Burkard ME, Kalinsky KM, Peppercorn J, Rugo HS, Carlson M, Cowden J, Maues J, McGlown S, Lustberg M. Patient-Centered Dosing Initiative, Salt Lake City, UT; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA; University of Wisconsin Carbone Cancer Center, Madison, WI; Winship Cancer Institute of Emory University, Atlanta, GA; University of California San Francisco Comprehensive Cancer Center, San Francisco, CA; Smilow Cancer Hospital, Yale Cancer Center, New Haven, CT.
P4-10-10 Effectiveness and feasibility of exercise-oncology programs in breast cancer patients using new technologies adapted to the COVID 19 new normality
Casla-Barrio S, Gil-Herrero L, Castellanos M. Spanish Cancer Asociation, Madrid, Spain.
P4-10-11
Eyebrow/eyelash loss among survivors

Cathcart-Rake E, Loprinzi CL, Couch F, Olson J, Dulmage B, Lustberg M, Larson N, Ruddy KJ. Saint Luke's Cancer Institute, Kansas City, MO; Mayo Clinic, Rochester, MN; Ohio State University, Columbus, OH; Yale Cancer Center, New Haven, CT.
P4-10-12 The relevance of chemobrain in breast cancer survivors: An Italian exploratory study to measure incidence and psycho-social impact
West T, Scaggiante B, Ceccherini R, Foladore S, Generali D, Versace F, Cavallero C. Lega Italiana Lotta Tumori - LILT, Trieste, Italy; Department of Life Sciences, University of Trieste, Trieste, Italy; Breast Cancer Unit - ASU GI, Trieste, Italy; Department of Medical, Surgery and Health Sciences, University of Trieste, Trieste, Italy; The University of Texas MD Anderson Cancer Center, Houston, TX.
P4-10-13 Area deprivation index and rurality in relation to financial toxicity among breast cancer surgical patients - Investigating geospatial differences in risk profiles
Corkum JP, Zhu V, Agbafe V, Chu C, Suarez Colen J, Greenup R, Offodile AC. 1MD Anderson, Houston, TX; Yale University, New Haven, CT.
P4-10-14 Association between depression and anxiety status of breast cancer patients undergoing adjuvant chemotherapy and chemotherapy-induced adverse events
Lv D, Lan B, Zhang L, Sun X, Yang M, Ma F. Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College; Chinese Academy of Medical Sciences Key Laboratory for National Cance, Beijing, China; National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital &Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, China; Department of Medical Oncology, Cancer Hospital of Huanxing Chaoyang District, Beijing, China; Comprehensive Oncology Department, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
P4-10-15 Whole-body vibration combined with physical exercise to treat aromatase inhibitor-induced musculoskeletal symptoms in breast cancer women: Results of a pilot randomized controlled study
Lippi L, de Sire A, Ammendolia A, Cisari C, Venetis K, Sajjadi E, Fusco N, Invernizzi M. Physical and Rehabilitative Medicine, Department of Health Sciences, University of Eastern Piedmont, Novara, Italy; Department of Medical and Surgical Sciences, University of Catanzaro "Magna Graecia", Catanzaro, Italy; Division of Pathology, IEO, European Institute of Oncology IRCCS, Milan, Italy; Infrastruttura Ricerca Formazione Innovazione (IRFI), Azienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo, Alessandria, Italy.
P4-10-16 Increased chemotherapy-induced ovarian reserve loss and impaired oocyte quality in a mouse ATM knock-down model: An augury for women with ATM-pathway-pathogenic-variants-associated breast cancer?
Oktay KH, Tan X, Szymanska-Vandendriessche K. Yale University School of Medicine, New Haven, CT.
P4-10-17
Alopecia among breast cancer survivors

Cathcart-Rake E, Loprinzi CL, Olson JE, Couch F, Dulmage B, Lustberg M, Larson N, Ruddy KJ. Saint Luke's Cancer Institute, Kansas City, MO; Mayo Clinic, Rochester, MN; Ohio State University, Columbus, OH; Yale Cancer Center, New Haven, CT.
P4-10-18 The effects of preoperative personalized music therapy associated with the patient-doctor relationship and surgical experience of patients with breast cancer (MARS)
Joo Y, Chung S, Kim S, Lee S, Ahn S-H, Lee J, Ko B, Kim J, Chung IY, Son BH, Kim HJ. Division of Breast Surgery, Department of Surgery, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea; Department of Psychiatry, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea; Department of Clinical Epidemiology and Biostatistics, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea.
P4-10-19
Aromatase inhibitors and bone health in elderly women with early breast cancer: Real-world data

Miranda Baleiras M, Vasconcelos de Matos L, Fernandes L, Neves MT, Alves F, Ferreira A, Miranda H, Martins A. Hospital de São Francisco Xavier, Centro Hospitalar de Lisboa Ocidental, Lisbon, Portugal; Centro Hospitalar de Lisboa Central, Lisbon, Portugal.
P4-10-20
Quality of life in Mexican young women with locally-advanced breast cancer: A cohort study

Villarreal-Garza C, Vaca-Cartagena BF, Becerril-Gaitan A, Platas A, Miaja M, Mesa-Chavez F, Ferrigno AS, Fonseca A, Cruz-Ramos M, Labra L, Bargallo-Rocha E, Mohar A. Breast Cancer Center, Hospital Zambrano Hellion TecSalud, Tecnologico de Monterrey, San Pedro Garza García, Mexico; Joven & Fuerte: Programa para la Atencion e Investigacion de Mujeres Jovenes con Cancer de Mama, Ciudad de Mexico, Mexico; Depto. Tumores Mamarios y Depto. de Investigacion, Instituto Nacional de Cancerologia, Ciudad de Mexico, Mexico.
P4-10-21
High-intensity interval training in breast cancer survivors: A systematic review

Tsuji K, Matsuoka YJ, Ochi E. Hosei University / Research Fellow of Japan Society for the Promotion of Science / National Cancer Center Japan, Tokyo, Japan; National Cancer Center Japan, Tokyo, Japan; Hosei University / National Cancer Center Japan, Tokyo, Japan.
P4-10-22
Patient reported symptoms and functional status in breast cancer

Torres S, Bayoumi A, Liu G, Kinupe Abrahao AB, Mitsakakis N, Krahn M, Trudeau M. IHPME, University of Toronto, Toronto, ON, Canada; St. Michael’s Hospital, Li Ka Shing Knowledge Institute, Toronto, ON, Canada; Division of Medical Oncology and Hematology,Department of Medicine, Princess Margaret Cancer Centre/University Health Network and University of Toronto, Toronto, ON, Canada; Americas Oncologia, São Paulo, Brazil; Children's Hospital of Eastern Ontario, Ottawa, ON, Canada; University Health Network, Toronto HealthEconomics and Technology Assessment (THETA) Collaborative, Toronto, ON, Canada; Sunnybrook Health Sciences Centre, Odette Cancer Centre, Toronto, ON, Canada.
P4-10-23 Combined analysis of PTEN and routinely assessed biomarkers reveals new high-risk subgroups of HR- or HER2+ breast cancers
Fusco N, Sajjadi E, Venetis K, Invernizzi M, Gambini D, Runza L, Ferrero S, Guerini-Rocco E. European Institute of Oncology (IEO), Milano, Italy; University of Eastern Piedmont - Azienda ospedaliera Santi Antonio e Biagio e Cesare Arrigo, Alessandria, Italy; Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico, Milano, Italy.
   
  Psychosocial, QOL, and Educational Aspects - Quality of Life Issues: Survivorship Research
P4-11-01 Development of a clinico-bio-behavioral model for cancer-related fatigue (CRF) incorporating inflammatory biomarkers and proteomic data
Di Meglio A, Christodoulidis S, Soldato D, Noce AD, Presti D, Havas J, Dubuisson F, Pistilli B, Camara-Clayette V, Charles C, Ganz PA, Bower J, Partridge AH, Jacquet A, Everhard S, Boyault S, André F, Cournede P-H, Michiels S, Pradon C, Vaz-Luis I. Institut Gustave Roussy, Villejuif, France; Centrale Supelec, Orsay, France; Bordeaux University Hospital, Bordeaux, France; University of California, Los Angeles, CA; Dana-Farber Cancer Institute, Boston, MA; UNICANCER, Paris, France; Centre Léon Bérard, Lyon, France.
P4-11-02
Prevalence and impact of fertility concerns in young women with breast cancer

Mannion S, Higgins A, Stewart EA, Khan Z, Shenoy C, Larson N, Nichols HB, Su HI, Partridge AH, Couch FJ, Olson JE, Ruddy K. Mayo Clinic, Rochester, MN; University of North Carolina, Chapel Hill, NC; University of California San Diego, La Jolla, CA; Dana Farber Cancer Institute, Boston, MA.
P4-11-03 Decisions and outcomes of young women with breast cancer regarding fertility preservation before cancer treatment and family building after treatment
Goldfarb SB, Thom B, Chang C, Abdo N, Carpio A, Semler R, Benedict C, Hershberger P, Kelvin JF, Gemignani ML. Memorial Sloan Kettering Cancer Center, New York, NY; Stanford University School of Medicine, Palo Alto, CA; University of Illinois, Chicago, IL.
P4-11-04 A randomized adaptive sequential selection trial of cryotherapy, compression therapy, and placebo to prevent taxane inducted peripheral neuropathy in patients with breast cancer
Accordino MK, Lee S, Leu C-S, Trivedi MS, Crew KD, Kalinsky KM, Rajhunathan R, Taboada A, Franks L, Honan E, Harden E, Law C, Hershman DL. Columbia University Medical Center, New York, NY; Winship Cancer Institute at Emory University, Atlanta, GA.
P4-11-05 How to stay sexually active and sexually well-functioning after breast cancer - Reporting from the SWEET study
Smedsland SK, Vandraas K, Bøhn S, Dahl A, Kiserud C, Brekke M, Falk R, Reinertsen K. Oslo University Hospital, Oslo, Norway; University of Oslo, Oslo, Norway.
P4-11-06 Effect of suppressed ovarian function on prognosis of premenopausal obese women with hormone receptor-positive breast cancer: A single-institute retrospective study
Ozaki Y, Masuda J, Kataoka A, Kogawa T, Abe T, Morizono H, Inagaki L, Hara F, Takano T, Ueno T, Ohno S. The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.
P4-11-07 Improfib: Impact of radiotherapy on fatigue in breast cancer survivors
Ghannam Y, Di Meglio A, Sarrade T, Jacquet A, Everhard S, Kirova Y, Peigneaux K, Guilbert P, Chara-Brunaud C, Blanchecotte J, Crehange G, Pasquier D, Racadot S, Bourgier C, Geffrelot J, Benyoucef A, Paris F, Auzac G, Vaz-Luis I, Rivera S. Radiotherapy Department, Gustave Roussy, Villejuif, France; Molecular Predictors and New Targets in Oncology, INSERM Unit 981, Gustave Roussy, Villejuif, France; UNICANCER, Paris, France; Institut Curie, Paris, France; Centre Georges-François Leclerc, Dijon, France; Jean Godinot, Reims, France; Institut de Cancérologie de Lorraine, Vandoeuvre Les Nancy, France; Institut de Cancérologie de l'Ouest - Paul Papin, Angers, France; Institut Curie, Saint Cloud, France; Centre Leon Bérard, Lyon, France; Institut du Cancer de Montpellier, Montpellier, France; Centre François Baclesse, Caen, France; Centre Henri Becquerel, Rouen, France; UMR Inserm 1232, Université de Nantes, Nantes, France.
P4-11-08 Impact of ovarian stimulation for fertility preservation in young women with breast cancer: Updated survival and pregnancy outcomes
Tesch ME, Wang Y, Lim C, Xu YH, Lee S, Perdrizet K, Yokom D, Warner E, Roberts J, Lohrisch C. BC Cancer, Vancouver, BC, Canada; University of Calgary, Calgary, AB, Canada; University of British Columbia, Vancouver, BC, Canada; Allan Blair Cancer Centre, Regina, SK, Canada; William Osler Health System, Brampton, ON, Canada; Trillium Health Partners, Credit Valley Hospital, Mississauga, ON, Canada; Sunnybrook Odette Cancer Centre, Toronto, ON, Canada; Pacific Centre for Reproductive Medicine, Vancouver, BC, Canada.
P4-11-09 Cancer-related cognitive impairment (CRCI) in early breast cancer (BC) survivors
Presti D, Joly F, Soldato D, Christodoulidis S, Noce AD, Havas J, Dubuisson F, Pistilli B, Camara-Clayette V, André F, Martin A-L, Jacquet A, Boyault S, Bièche I, Coutant C, Cournede P-H, Michiels S, Pradon C, Vaz-Luis I, Di Meglio A. Gustave Roussy, Villejuif, France; Centre François Baclesse, Caen, France; Centrale Supelec, Orsay, France; UNICANCER, Paris, France; Centre Léon Bérard, Lyon, France; Institut Curie, Paris, France; Centre George-Francois Leclerc, Dijon, France.
P4-11-10 Association of sports activity during the first five years of survival with quality of life among Chinese breast cancer survivors
Yeo W, Lei Y, Cheung K, Lee R, Kwok C, Cheng A, Cheng A, Mo F, Ho S. Chinese University of Hong Kong, Hong Kong, China; Chinese University of Hong Kong, Hong Kong, Hong Kong; Princess Margaret Hospital, Hong Kong, Hong Kong.
P4-11-11 Effect of home-based smartphone-supported high-intensity interval training on cardiorespiratory fitness in breast cancer survivors: A randomized controlled trial of the habit-B program
Ochi E, Tsuji K, Narisawa T, Shimizu Y, Kuchiba A, Suto A, Jimbo K, Takayama S, Ueno T, Sakurai N, Matsuoka YJ. Hosei University / National Cancer Center Japan, Tokyo, Japan; Hosei University / Research Fellow of Japan Society for the Promotion of Science / National Cancer Center Japan, Tokyo, Japan; Musashino University / National Cancer Center Japan, Tokyo, Japan; National Cancer Center Hospital, Tokyo, Japan; National Cancer Center Japan / Kanagawa University of Human Services, Tokyo, Japan; SUSMED, Tokyo, Japan; Cancer Solutions, Tokyo, Japan; National Cancer Center Japan, Tokyo, Japan.
P4-11-12 Integrating the patient and partner distress and perceptions about prognosis in women with metastatic breast cancer guides the medical oncology consultation
Mortimer J, Waisman J, Yuan Y, Lavasani S, Stewart D, Sedrak M, Patel N, Bitz C, Clark K, Razavi M, Loscalzo MJ. City of Hope, Duarte, CA.
P4-11-13 Prevalence of treatment-related symptoms in patients with breast cancer undergoing (neo)adjuvant endocrine therapy with or without chemotherapy for early stage breast cancer
Mortimer J, Moore S, Patel N, Sedrak M, Stewart D, Yuan Y, Waisman J, Bradford B, Loscalzo M, Clark K, Razavi M. City of Hope, Duarte, CA.
P4-11-14 Importance of work and work-related needs among survivors living with metastatic breast cancer
Carroll CB, Sesto ME, Zhang X, Chen KB, Terhaar A, Wilson AS, Tevaarwerk AJ. University of Wisconsin Carbone Cancer Center, Madison, WI; University of Wisconsin School of Medicine and Public Health, Madison, WI; North Carolina State University, Raleigh, NC; University of Wisconsin Trace Research and Development Center, Madison, WI.
P4-11-15 Breast cancer survivors vulvo-vaginal atrophy symptoms: Morphological aspects unveiled
de Mello Bianchi-Ferraro AMH, Lugollo AF, Jarmy-di Bella ZI, Sartori MG, Speck NMG, Patriarca MT, de Cassiade Maio Dardes R, Cruz Cantarelli G, Furtado Roberto M, Dedonato C, Caceres Nogueira MC, Campos MLP, Dias Oliveira C, Facina G, Nazaro ACP, Girão MJBC. Federal University of São Paulo, São Paulo, Brazil.
P4-11-16 Feasibility and patient satisfaction with a smartphone application to improve medication adherence among patients with breast cancer
Accordino MK, Ulene S, Honan E, Trivedi MS, Crew KD, Harden E, Law C, Hershman DL. Columbia University Medical Center, New York, NY.
P4-11-17 Return to work after breast cancer: Disparities among patients treated in public and private hospitals in Brazil
Landeiro L, Barros LHC, Neumann LTV, Santos AM, Siqueira ACA, Kaliks R. Grupo Oncoclínicas - Bahia, Salvador, Brazil; Instituto Oncoguia, São Paulo, Brazil.
P4-11-18 Withdrawn
P4-11-19 Utilization of the RE-AIM framework for evaluating the implementation of group medical visit for low-income breast cancer survivors
Trejo E, Velazquez AI, Castillo E, Cicerelli B, McBride R, Burke NJ, Dixit N. University of California, San Francisco (UCSF), San Francisco, CA; San Francisco Department of Public Health, San Francisco, CA.
P4-11-20 Attitudes and factors influencing contraception use over time in premenopausal women with early breast cancer in the prospective CANTO study
Lambertini M, Massarotti C, Havas J, Pistilli B, Martin A-L, Jacquet A, Coutant C, Coussy F, Dhaini Merimeche A, Lerebours F, Tredan O, Jouannaud C, Rigal O, Fournier M, Soulie P, Franzoi MA, Del Mastro L, Partridge AH, Andre F, Vaz-Luis I, Di Meglio A. University of Genova - IRCCS Ospedale Policlinico San Martino, Genova, Italy; Gustave Roussy, Villejuif, France; Unicancer, Paris, France; Centre Georges-François Leclerc, Dijon, France; Institut Curie, Paris, France; Centre Alexis Vautrin, Vandoeuvre Les Nancy, France; Institut CURIE, Saint Cloud, France; Centre Léon Berard, Lyon, France; Institut Jean Godinot, Reims, France; Centre Henri Becquerel, Rouen, France; Institut Bergonié, Bordeaux, France; Institut de Cancérologie de L'ouest -Paul Papin, Angers, France; Dana-Farber Cancer Institute, Harvard Medical School, Harvard Medical School, Boston, MA.
P4-11-21 Withdrawn
P4-11-22 Arm lymphedema and socioeconomic factors in an urban cancer center
Choi L, Assad H, Chen S, Demeere T, Jang H, Weisberg E, Kosir MA. Wayne State University School of Medicine, Detroit, MI; Wayne State University, Detroit, MI; Detroit Medical Center, Detroit, MI; Karmanos Cancer Institute, Detroit, MI.
P4-11-23 Project SOAR: The strong black woman schema in the breast cancer context
Denyse T, Martin KJ, Pageot YK, deLuz KD, Kim JHJ, Owoyemi P Stanton AL. Carrie's TOUCH, Sacramento, CA; UCLA, Los Angeles, CA.
P4-11-24 Patient's point of view on how to promote adherence to adjuvant endocrine therapy (ET): A large french survey
Akla S, Rassy E, Di-Meglio A, Martin E, Havas J, Rieutord A, Paci A, Combarel D, Fasse L, Scotte F, Jacob G, Bergognoux A, Delaloge S, Vas Luis I, Pistilli B. Institut Gustave Roussy, Villejuif, France; Les Seintinelles, Paris, France; L'association Odyssea, PARS, France.
P4-11-25 Burden of financial toxicity in an underserved population of breast cancer survivors
Mehta A, Namm J, D'Errico E, Lau E, Lum S, Nagaraj G. Loma Linda University Medical Center, Loma Linda, CA; Loma Linda University Cancer Center, Loma Linda, CA; Loma Linda University School of Nursing, Loma Linda, CA.
P4-11-26 The importance of physical exercise in cardiovascular fitness in breast cancer survivors. A cross sectional study: WIM 2.0
Gil Herrero L, Pollán Santamaría M, Martín Jimenez M, López Tarruella S, Castellanos Montealegre M, Casla Barrio S. Spanish Cancer Association, Madrid, Spain; Instituto de Salud Carlos III, Madrid, Spain; Hospital Universitario Gregorio Marañón, Madrid, Spain.
P4-11-27 A multimodal and personalized digital companion to help survivors of breast cancer (BC) manage side effects of adjuvant endocrine therapy (ET): A qualitative exploration
Martin E, Di Meglio A, Lapidari P, Presti D, Soldato D, Degousee L, Aupomerol M, Pistilli B, Fasse L, Boinon D, Scotte F, Menvielle G, Dumas A, Lazorthes C, Benhamou J, Pozza M, Martin-Neuville R, Helleringer N, Eelkema J, Andre F, Vaz-Luis I, Franzoi MA. Gustave Roussy, Villejuif, France; Sorbonne Université, Inserm, Institut Pierre Louis d'Epidémiologie et Santé Publique (IPLESP), Paris, France; Inserm Unit 1123, Unité ECEVE, Université de Paris, Paris, France; Resilience Care, Paris, France.
P4-11-28 Collecting quality of life information in a cohort of breast cancer survivors- Integrating electronic data collection into clinical practice
Amat C, Fuentes Á, Grau I, Lozano-Rubí R, Martinez-Sáez O, Chic N, Adamo B, Vidal M, Fernandez I, Valachis A, Kosmidis T, Kokkonidis M, Muñoz M. Fundació Clínic per la Recerca Biomèdica, Barcelona, Spain; Fundación Internet Salud y Sociedad, Barcelona, Spain; Hospital Clínic de Barcelona, Barcelona, Spain; Department of Oncology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden; Care Across Ltd., London, United Kingdom; Intrasoft International S.A., Research and Innovation Development, Luxembourg, Luxembourg.
P4-11-29 Evaluating potential overuse of surveillance care in cancer survivors
Sheng JY, Snyder CF, Smith KC, DeSanto J, Mayonado N, Rall S, White S, Blackford AL, Johnston FM, Joyner RL, Mischtschuk J, Peairs KS, Thorner E, Tran PT, Wolff AC, Choi Y. Johns Hopkins University, Baltimore, MD; TidalHealth, Salisbury, MD.
P4-11-30 Breast cancer follow-up. Patients expectations versus reality
Zaluska-Kusz J, Litwiniuk M. Wielkopolskie Centrum Onkologii, Poznan, Poland.
P4-11-31 Health care professionals’ perspectives on less intensive post-treatment surveillance after breast cancer for women with low risks for recurrences
Ankersmid JW, Drossaert CHC, van Uden - Kraan CF, Strobbe LJA, Siesling S. Santeon Hospital Group, Utrecht, Netherlands; University of Twente, Enschede, Netherlands; Canisius Wilhelmina Hospital, Nijmegen, Netherlands.
P4-11-32 Patient-reported outcome after oncoplastic breast conservation surgery using level I or II techniques without contralateral symmetrization
Deshmane V, Raniwala A, Cardoza C. PD Hinduja Hospital, Mumbai, India.
P4-11-33 Continuous glucose monitoring and hyperglycemia during chemotherapy for early-stage breast cancer
Accordino MK, Spivack JH, Ulene S, Honan E, Trivedi MS, Crew KD, Harden E, Law C, Hershman DL. Columbia University Medical Center, New York, NY.
P4-11-34 An integrated clinical, behavioral and biological model to predict the risk of weight gain among breast cancer survivors (BCS)
Soldato D, Di Meglio A, Pradon C, Noce AD, Presti D, Havas J, Dubuisson F, Pistilli B, Camara-Clayette V, André F, Jacquet A, Everhard S, Boyault S, Cournede P-H, Michiels S, Vaz-Luis I, Christodoulidis S. Gustave Roussy, Villejuif, France; UNICANCER, Paris, France; Centre Léon Bérard, Lyon, France; Centrale Supelec, Orsay, France.
   
  Psychosocial, Quality of Life and Educational Aspects:Psychosocial, QOL & Educational Aspects-Other
P4-12-01 Adherence with adjuvant endocrine therapy with or without Palbociclib in the PALLAS trial
Shinn E, Zahrieh D, DeMichele A, Zdenkowski N, Lemieux J, Mao J, Bjelic-Radisic V, Naughton M, Pfeiler G, Gelmon K, Mayer I, Egle D, Zoppoli G, Traina T, Jiménez MM, Novoa SA, Haddad T, Chan A, Ring AE, Wolff A, Lorenz JJP, Sabanathan D, Burstein H, Nowecki ZI, Pristauz-Telsnigg G, Brufsky A, Bellet-Ezquerra M, Foukakis T, Novik Y, Rubovszky G, Muehlbacher K, Metzger O, Goulioti T, Law E, Partridge A, Carey L, Zoroufy A, Hlauschek D, Fesl C, Mayer E, Gnant M. University of Texas M. D. Anderson, Houston, TX; The Mayo Clinic/Alliance, Rochester, MN; University of Pennsylvania/ECOG, Philadelphia, PA; Calvary Mater Newcastle, Waratah, NSW, Australia; CHU de Québec-Université Laval, Québec, QC, Canada; Memorial Sloan Kettering Cancer Center/AFT, New York, NY; Helios University Clinic Wuppertal, Breast Unit University Witten/Herdecke, Wuppertal, Germany; Ohio State University/Alliance, Columbus, OH; Austrian Breast Cancer Study Group (ABCSG), Vienna, Austria; University of British Columbia, Vancouver, BC, Canada; Vanderbilt University/ECOG, Nashville, TN; Medical University Innsbruck, Innsbruck, Austria; University Hospital San Martino - National Cancer Institute, Genoa, Italy; Hospital General Universitario Gregorio Marañón, Madrid, Spain; A Coruña University Hospital, A Coruña, Spain; Breast Cancer Research Centre-WA, Nedlands, WA, Australia; The Royal Marsden, East Sussex, United Kingdom; Johns Hopkins University/ECOG, Baltimore, MD; Hospital General Universitario de Alicante, Spain, Alicante, Spain; Lakeside Specialist Breast Clinic and Nepean Cancer Care Centre, Norwest, NSW, Australia; Dana-Farber Cancer Institute/Alliance, Boston, MA; The Maria Sklodowska Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland; Medical University of Graz, Graz, Austria; University of Pittsburgh Cancer Institute, Pittsburgh, PA; Vall d’Hebron Institute of Oncology, Barcelona, Spain; Karolinska Institute and University Hospital, Solna, Sweden; New York University, New York, NY; National Institute of Oncology, Budapest, Hungary; Breast International Group, Brussels, Belgium; Pfizer, Chicago, IL; University of North Carolina/Alliance, Chapel Hill, NC; Dana-Farber Cancer Institute/AFT, Boston, MA; Medical University of Vienna, ABCSG, Vienna, Austria.
P4-12-02 Improving patient-reported outcome data capture for clinical research: ePRO in ISPY 2, a phase 2 breast cancer study
Northrop A, Christofferson A, Melisko M, Sit L, Olunuga E, Mittal A, Goldman A, Brown T, Heditsian D, Parker B, Brain S, Simmons C, Taboada A, Ruddy KJ, Hieken T, Piltin M, Cook K, Salvador C, Mainor C, Afghahi A, Tevis S, Blaes A, Kang I, Melin S, Esserman L, Asare A, Hershman DL, Basu A. University of California San Francisco, San Francisco, CA; University of Alabama at Birmingham, Birmingham, AL; Living Beyond Breast Cancer, Bala Cynwyd, PA; Columbia University, New York, NY; Mayo Clinic, Rochester, MN; Oregon Health & Sciences University, Portland, OR; Georgetown University, Washington, DC; University of Colorado, Aurora, CO; University of Minnesota, Minneapolis, MN; University of Southern California, Los Angeles, CA; Wake Forest University, Winston-Salem, NC; Quantum Leap Healthcare Collaborative, San Francisco, CA.
P4-12-03 Assessment of quality of life (QoL) in patients with metastatic breast cancer (MBC) in clinical practice: A real-world multi-country survey
Cardoso F, Rihani J, Aubel D, Moore A, Harmer V, Harbeck N, Casas A, Haftchenary S, Pathak P, Schumacher-Wulf E. Champalimaud Clinical Center/Champalimaud Foundation, Lisbon, Portugal; King Hussein Cancer Center, Amman, Jordan; Novartis Pharmaceuticals Corporation, East Hanover, NJ; Adelphi Real World, Cheshire, United Kingdom; Imperial College Healthcare NHS Trust, London, United Kingdom; Breast Center, Department of Obstetrics and Gynecology, LMU University Hospital Munich, Munich, Germany; University Hospital Virgen del Rocio, Sevilla, Spain; Novartis Pharmaceuticals Canada, Montreal, QC, Canada; Novartis Ireland Ltd, Dublin, Ireland; Mamma Mia! Breast Cancer Magazine, Kronberg, Germany.
P4-12-04 Healthcare utilization and symptoms among hospitalized patients with breast cancer
Vidula N, Kaslow-Zieve E, Qian C, Neckermann I, Gaufberg E, Vyas C, Newcomb R, Johnson PC, Lage D, Shin J, Nipp R. Massachusetts General Hospital, Boston, MA.
P4-12-05 Benefit of multidisciplinary consultation at initiation of oral antineoplastic agents in metastatic breast cancer patients
Morel A, Jacobs M, Da Silva A, Allouache D, Hrab I, Segura C, Villemin M, Boscher C, Johnson A, Ceintre C, Charles R-M, Lahaye F, Lequesne J, Divanon F, Levy C, Emile G. Centre François Baclesse, Caen, France.
P4-12-06 A patient experience model of diagnosis of pregnancy associated breast cancer (PABC)
Hamlish T, Strom S, Ganschow P. University of Illinois at Chicago, Chicago, IL.
P4-12-07 Incremental benefit of an interdisciplinary care team model for resource identification in adolescents and young adults with breast cancer
Gruen L, Lee-Miller C, Parkes A. University of Wisconsin School of Medicine and Public Health, Madison, WI.
P4-12-08 Accuracy of Patient Self-Reported Breast Cancer Disease Characteristics Compared to the Medical Record in a Trial of the Outcomes4MeDigital Health App
Isakoff SJ, Glieberman E, Said M, Kwak AH, O’Rourke EA, Stroiney A, Spring L, Moy B, Bardia A, Horick N, Peppercorn J. Massachusetts General Hospital, Boston, MA; Outcomes4Me Inc, Cambridge, MA.
P4-12-09 Implications of protocol modifications and treatment delays for breast cancer patient experiences during Covid-19
Hamlish T, Papautsky EL. University of Illinois at Chicago, Chicago, IL.
P4-12-10 Cancer worry among healthy BRCA mutation carriers in Austria: A pilot study
Parger A-M, Muhr D, Singer CF, Tan YY. Medical University of Vienna, Vienna, Austria.
P4-12-11 Eq-5d-5l utility scores for patients with breast cancer
Torres S, Bayoumi A, Trudeau M, Kinupe Abrahao AB, Mitsakakis N, Krahn M, Liu G. IHPME- University of Toronto, Toronto, ON, Canada; St. Michael’s Hospital, Li Ka Shing Knowledge Institute, Toronto, ON, Canada; Sunnybrook Health Sciences Centre, Odette Cancer Centre, Toronto, ON, Canada; Americas Oncologia, São Paulo, Brazil; Children's Hospital of Eastern Ontario, Ottawa, ON, Canada; University Health Network, Toronto Health Economics and Technology Assessment (THETA) Collaborative, Toronto, ON, Canada; Division of Medical Oncology and Hematology, Department of Medicine, Princess Margaret Cancer Centre/University Health Network and University of Toronto, Toronto, ON, Canada.
P4-12-12 Assessing the impact of the COVID-19 pandemic on cancer treatment decision-making and care experiences
Alsafar N, Hao D, Alimohamed N, Samnani S, Lupichuk S. Tom Baker Cancer Centre, Calgary, AB, Canada.
P4-12-13 Psychosocial aspects in relation to clinical status of breast cancer patients after prolonged COVID pandemic in south India: A observational survey study
Krishnan C. Madras Medical College, Chennai, India. .
P4-12-14 Assessing patients perceptions on hormone therapy for breast cancer: Insights from a Brazilian patient group
Montemor MS, Neumann LTV, Siqueira ACA, Barros LHC, Sanches SM. Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil; Instituto Oncoguia, São Paulo, Brazil; Intituto Oncoguia, São Paulo, Brazil; Ac Camargo Cancer Center, São Paulo, Brazil.